Heparin prodrugs and drug delivery stents formed therefrom
AssigneeAbbott Cardiovascular Systems Inc.
InventorsSyed Faiyaz Ahmed Hossainy, Ni Ding
Life of this patent
Estimating the term…
Abstract
A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Claims9
A prodrug of a drug, said prodrug comprising the drug, heparin, and a polymer,
- wherein the heparin is covalently linked to the polymer,
- wherein the drug is covalently linked to the heparin,
- wherein the drug is not pharmacologically active in the presence of the covalent linkage between the drug and the heparin,
- wherein the covalent linkage of the drug to the heparin is either hydrolytically or enzymatically unstable,
- wherein the covalent linkage between the drug and the heparin is hydrolytically or enzymatically cleaved under in vivo conditions, and
- wherein the polymer is selected from the group consisting of poly(L-lysine-co-hyaluronic acid) (PLL-co-HA), poly(L-lysine-co-phosphoryl choline) (PLL-co-PC), poly(ethylimine-co-hyaluronic acid) (PEI-co-HA), poly(ethylimine-co-phosphoryl choline) (PEI-co-PC), poly(L-lysine-g-hyaluronic acid) (PLL-g-HA), poly(L-lysine-g-phosphoryl choline) (PLL-g-PC), poly(ethylimine-g-hyaluronic acid) (PEI-g-HA), and poly(ethylimine-g-phosphoryl choline) (PEI-g-PC).
Dependencies are inferred from the claim text.